Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Best Momentum Stocks to Buy for January 3rd
by Zacks Equity Research
SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
New Strong Buy Stocks for January 3rd
by Zacks Equity Research
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
by Sundeep Ganoria
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 82.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
by Zacks Equity Research
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
by Zacks Equity Research
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.
Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.
Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD
by Zacks Equity Research
The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.